Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States

Clinical Therapeutics

Volumn 31, Issue 3, 2009, Pages 644-656

  Esposito, Dominick ^a   Wahl, Peter ^b   Daniel, Gregory ^b   Stoto, Michael A ^c   Haim Erder, M ^d   Croghan, Thomas W ^a,e  

^a MATHEMATICA POLICY RESEARCH   (United States)

^b HEALTHCORE INC   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adherence; antidepressant; depression; use pattern

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GENERIC DRUG; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DRUG COST; DRUG FORMULATION; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL INFORMATION; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PANIC; PATIENT COMPLIANCE; PRESCRIPTION; TREATMENT DURATION; UNITED STATES;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DATABASES AS TOPIC; DEPRESSION; DRUG COSTS; DRUG PRESCRIPTIONS; DRUGS, GENERIC; FEMALE; FLUOXETINE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PAROXETINE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; UNITED STATES;

EID: 64849100165     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.03.012     Document Type: Article

References (38)

1. Vaswani M., Linda F.K., and Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 85-102
2. Croghan T.W., Schoenbaum M., Sherbourne C.D., and Koegel P. A framework to improve the quality of treatment for depression in primary care. Psychiatr Serv 57 (2006) 623-630
3. Simon G.E. Choosing a first-line antidepressant: Equal on average does not mean equal for everyone. JAMA 286 (2001) 3003-3004
4. Tai-Seale M., Croghan T.W., and Obenchain R. Determinants for antidepressant treatment compliance: Implications for policy. Med Care Res Rev 57 (2000) 491-512
5. Polsky D., Onesirosan P., Bauer M.S., and Glick H.A. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. J Clin Psychiatry 63 (2002) 156-164
6. Gartlehner G., Gaynes B.N., Hansen R.A., et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med 149 (2008) 734-750 Summary for patients in:
7. Gartlehner G., Gaynes B.N., Hansen R.A., et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med 149 (2008) 156
8. Rush A.J., Trivedi M.H., Wisniewski S.R., et al., for the STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354 (2006) 1231-1242
9. Trivedi M.H., Fava M., Wisniewski S.R., et al., for the STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354 (2006) 1243-1252
10. Kasper S., Spadone C., Verpillat P., and Angst J. Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis. Int Clin Psychopharmacol 21 (2006) 105-110
11. Wade A., and Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 22 (2006) 2101-2110
12. Colonna L., Andersen H.F., and Reines E.H. A randomized, double blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 21 (2005) 1659-1668
13. Moore N., Verdoux H., and Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20 (2005) 131-137
14. Burke W.J., Gergel I., and Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63 (2002) 331-336
15. Kasper S., de Swart H., and Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatric Psychiatry 13 (2005) 884-891
16. Melfi C.A., Chawla A.J., Croghan T.W., et al. The effects of adherence to antidepressant guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55 (1998) 1128-1132
17. Reimherr F.W., Amsterdam J.D., Quitkin F.M., et al. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 155 (1998) 1247-1253
18. Sood N., Treglia M., Obenchain R.L., et al. Determinants of antidepressant treatment outcome. Am J Manag Care 6 (2000) 1327-1336
19. International Classification of Diseases, Ninth Revision, Clinical Modification (2006), Ingenix, Salt Lake City, Utah
20. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 150 Suppl (1993) 1-26
21. Schulberg H.C., Katon W., Simon G.E., and Rush A.J. Treating major depression in primary care practice: An update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 55 (1998) 1121-1127
22. Weilburg J.B., O'Leary K.M., Meigs J.B., et al. Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatric Serv 54 (2003) 1233-1239
23. Croghan T.W., Lair T.J., Engelhart L., et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 48 (1997) 1420-1426
24. Russell J.M., Berndt E.R., Miceli R., et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care 5 (1999) 597-606
25. Dunn R.L., Donoghue J.M., Ozminkowski R.J., et al. Longitudinal patterns of antidepressant prescribing in primary care in the UK: Comparison with treatment guidelines. J Psychopharmacol 13 (1999) 136-143
26. Mullins C.D., Shaya F.T., Meng F., et al. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. Clin Ther 28 (2006) 297-305
27. Akincigil A., Bowblis J.R., Levin C., et al. Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care 45 (2007) 363-369
28. Hirano K., and Imbens G. Estimation of causal effects using propensity score weighting: An application to data on right heart catheterization. Health Service Outcome Res Method 2 (2001) 259-278
29. Rosenbaum P. Model-based direct adjustment. J Am Stat Assoc 82 (1987) 387-394
30. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
31. Current Procedural Terminology (2006), American Medical Association, Chicago, Ill
32. Generic Product Identifier Code. http://www.medispan.com Accessed February 19, 2009
33. Demyttenaere K., Enzlin P., Dewé W., et al. Compliance with antidepressants in a primary care setting, 2: The influence of gender and type of impairment. J Clin Psychiatry 62 suppl 22 (2001) 34-37
34. Linden M., Gothe H., Dittman R.W., and Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 20 (2000) 523-530
35. DiMatteo M.R., Lepper H.S., and Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160 (2000) 2101-2107
36. Joyce G.F., Escarce J.J., Solomon M.D., and Goldman D.P. Employer drug benefit plans and spending on prescription drugs [published correction appears in JAMA. 2002;288:2409]. JAMA 288 (2002) 1733-1739
37. Huskamp H.A., Deverka P.A., Epstein A.M., et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349 (2003) 2224-2232
38. Gibson T.B., Mark T.L., Axelsen K., et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 12 Spec (2006) SP11-SP19